Beam Therapeutics

Contributing Author

Recent Articles by Beam Therapeutics

Jan-11	Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition BEAM GlobeNewswire
Dec-18	Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference BEAM GlobeNewswire
Dec-06	Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting BEAM GlobeNewswire
Nov-12	Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference BEAM GlobeNewswire
Nov-04	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates BEAM GlobeNewswire
Nov-03	Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting BEAM GlobeNewswire
Aug-25	Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences BEAM GlobeNewswire
Aug-14	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease BEAM GlobeNewswire
Aug-05	Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
Jun-13	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress BEAM GlobeNewswire
Jun-03	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease BEAM GlobeNewswire
May-29	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
May-14	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress BEAM GlobeNewswire
May-13	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference BEAM GlobeNewswire
May-12	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
May-06	Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights BEAM GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.